News & stories

News | Apr 26, 2023

J&J must stop blocking generic versions of lifesaving TB drug

J&J’s patent monopoly continues to keep bedaquiline out of reach.

Story | Mar 23, 2023

How to end TB: Teach it at school

MSF has developed a TB education curriculum that empowers educators and learners to become TB advocates.

News | Mar 23, 2023

MSF applauds rejection of J&J attempt to extend TB drug patent

The rejection of the salt form of bedaquiline is welcome news for people with drug-resistant tuberculosis.

News | Mar 22, 2023

World TB Day: More people need access to testing and treatment

MSF calls on governments and donors to speed up access to new, improved treatment for drug-resistant tuberculosis.

Story | Feb 22, 2023

Ukraine: "No one is spared from the impact of this war."

MSF-USA Executive Director Avril Benoît on the growing medical and mental health needs in the country

News | Dec 21, 2022

MSF trial finds better treatment for people with TB

Results published in the New England Journal of Medicine today show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of patients

Story | Dec 20, 2022

Forgotten Emergencies 2022: MSF responds

News | Dec 15, 2022

WHO recommends TB regimen found effective by MSF clinical trial

Story | Dec 09, 2022

Afghanistan: People with tuberculosis face multiple barriers to accessing treatment

Story | Dec 08, 2022

2022: A year of bearing witness

We bear witness and speak out. Read stories from MSF staff about what this work means to them.